Compare · DRUG vs NVO
DRUG vs NVO
Side-by-side comparison of Bright Minds Biosciences Inc. (DRUG) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRUG and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 210.7x DRUG ($872.6M).
- Over the past year, DRUG is up 175.0% and NVO is down 34.2% - DRUG leads by 209.2 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 1 for DRUG).
- NVO has more recent analyst coverage (25 ratings vs 8 for DRUG).
- Company
- Bright Minds Biosciences Inc.
- Novo Nordisk A/S
- Price
- $89.32+1.16%
- $41.18+6.93%
- Market cap
- $872.6M
- $183.82B
- 1M return
- +20.09%
- +13.32%
- 1Y return
- +174.96%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 5
- Recent ratings
- 8
- 25
Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DRUG
- Jefferies initiated coverage on Bright Minds Biosciences with a new price target
- Bright Minds Biosciences to Present at Upcoming Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.
- SEC Form 6-K filed by Bright Minds Biosciences Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.
- SEC Form 6-K filed by Bright Minds Biosciences Inc.
- Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
- SEC Form 6-K filed by Bright Minds Biosciences Inc.
- SEC Form 424B5 filed by Bright Minds Biosciences Inc.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S